J&J's (JNJ) and Pfizer' (PFE) bapineuzumab drug showed signs that it is able to reduce...
J&J's (JNJ) and Pfizer' (PFE) bapineuzumab drug showed signs that it is able to reduce nerve-cell damage in the brain and the buildup of amyloid plaque, which has been linked to Alzheimer's disease. While bapineuzumab was unable to improve patients' memory or thinking, as disclosed last month, the drug could eventually be used as a preventative measure.
From other sites
Video at CNBC.com (Jul 20, 2015)
Video at CNBC.com (Jul 14, 2015)
Video at CNBC.com (May 27, 2015)
at CNBC.com (May 22, 2015)
Video at CNBC.com (May 20, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs